THE FUTURE OF OPTIMIZED TENDON AND LIGAMENT REPAIR IS HERE
VISION: To optimize the treatment of tendon and ligament injuries in both humans and animals
MISSION: Our mission is to focus on patients by bringing the dedication and skill of our team to enable an innovative therapy to optimize tendon and ligament healing to decrease the disability, suffering, and economic burden for patients, payers, and suppliers.
Scientific Innovation: To never accept current approaches and outcomes as acceptable, particularly when inequities exist that can be addressed by creative careful science.
Integrity: To adhere to the highest standards and professionalism for ethics and responsibility to the patients.
Value: To increase value for patients by improving outcomes and knowing that by putting the patient first, the company will do well. Efforts focus on demonstrating the benefit of PAX's approach as efficiently as possible to bring this breakthrough to patients and value to investors, as soon as possible.
Excellence: To deliver the highest quality service and products to our investors and patients through exceptional leadership and a focused, dedicated and insightful team.
Board of Directors
Co-Founder & Executive Chairman
Co-Founder and CSO
CFO and VP, Operations and Business
Tendon Repair Expertise
Equine Tendon Injuries
PAX Therapeutics is a US-based company dedicated to optimize healing of tendon and ligament injuries to restore full mobility and improved function faster than current approaches.
Spun out of Brown University by a Harvard Medical School-trained surgeon-scientist, PAX Therapeutics provides a patented and unique approach that capitalizes on the advances in gene delivery that have made vectors a safe technology for use even in children.
Research over 15 years performed in the founder’s academic lab led to the specific patented combination of vector and growth factor gene and mechanism of healing for use for both tendons and ligaments and for human and veterinary applications.
Paul Liu, MD, MA, MA ad eundum, Co-Founder & Executive Chairman
Paul is Chair and Professor of Plastic Surgery at Brown University. He was educated at Harvard Medical School and Oxford University, where he was a Marshall Scholar. Paul was trained in general surgery and plastics at the Brigham / Children’s / Harvard. He is Past President of the Wound Healing Society, and leads a clinical department of 10 surgeons and 40 employees with revenues of ~$25 million/year.
Margaret A. Liu, MD, DSchc, MDhc, CEO
Margaret is also a Harvard Medical School graduate and a world-renowned expert in the fields of gene therapy, vaccines and immunotherapy. She has been a Director, then Advisory Council member, of the American Society for Gene and Cell Therapy, Vice-President of Vaccines and Gene Therapy at Chiron, Senior Advisor for the Bill & Melinda Gates Foundation, and board member at Transgene, Sangamo, Ipsen, and MacroGenics, among other executive, board, and SAB positions. Margaret is Hedersdoktor (Honorary Doctor) with Scientific Affiliation at the Karolinska Institutet in Stockholm, and Adjunct Full Professor at the University of California, San Francisco.
Xiao Tian Wang, MD, Co-founder & Chief Scientific Officer
Xiao is a Research Assistant Professor at Brown University and has been involved in gene therapy research with Dr. Paul Liu for 20 years. She developed the AAV2-VEGF vector, and the work (this project) won the 3M Award of Excellence in Translational Regenerative Science at the 2012 WHS Annual Meeting.
Sanjay Gokhale, VP of Corporate Development & CFO
Sanjay has more than three decades of experience in Investment Banking, Venture Capital, Corporate Development and Entrepreneurship. He has been involved in M&A advisory assignments, as well as financing and licensing transactions valued in excess of $10 billion. Sanjay holds a Bachelor of Chemical Engineering degree from the Institute of Chemical Technology in India, and an MBA from Rice University in Houston, Texas.
Robert G. Johnson, MD, PhD, Board Member and Advisor
Robert received his MD-PhD from UPenn, and has served on the medical faculties of Harvard Medical School and UPenn. He was CEO of KOSAN Pharmaceuticals, and is now COO for GenVivo, Inc. developing gene therapy cancer therapeutics and managing their clinical trials and intellectual property.
Richard Junghans, MD, PhD, Advisor for Clinical Trials
Dick earned his PhD in Immunology from Caltech, then attended medical school at U Miami. He has patented and developed armed targeted T-cell therapies for several cancers, and has completed multiple gene therapy clinical trials that afford him unique insight into FDA requirements and reporting. He is an attending oncologist at Tufts University School of Medicine in Boston.
Jin Bo Tang, MD, Scientific Advisor for Tendon and Ligament Models
Jin is an Adjunct Professor of Surgery in the Department of Plastic Surgery at Alpert Medical School of Brown University, and Professor and Chairman of Hand Surgery at Nantung University Medical School, Nantung, China. He is the world’s foremost authority on flexor tendon injuries, chairing the World Health Organization’s Taskforce on Tendon Injuries. He is also the Editor in Chief of the European Journal of Hand Surgery, London, UK.
Thomas P. Schaer, VMD, Equine Tendon Injuries
Tom received his VMD from the University of Pennsylvania School of
Veterinary Medicine and did his internship in Equine Medicine at the Rood Riddle Equine Hospital. He returned to the PennVet New Bolton Center for his residency in addition to being a Mack Technology Fellow at the Wharton School. He is now on the Faculty as a Staff Veterinarian at the UPenn School of Veterinary Medicine and holds a position at the Institute for Medical Translation at the New Bolton Center as well as being an Executive Committee Member, Penn Health-Tech- Center for Health, Devices and Technology.